Organization
Brigham and Women's Hospital, Boston, MA
5 abstracts
Abstract
SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.Org: UT Health San Antonio, San Antonio, TX, The Ohio State University, Columbus, OH, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, University of Chicago Medical Center, Chicago, IL, SWOG Cancer Research Network, San Antonio, TX,
Abstract
Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.Org: Artera, Vancouver, BC, Canada, Department of Pathology, University of California San Francisco, San Francisco, CA, Tulane University, New Orleans, LA, University of California, San Francisco, San Francisco, CA, Case Western Reserve University, Cleveland, OH,
Abstract
Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors.Org: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, New York, NY, USA, University of Massachusetts Medical School, Worcester, MA, Desai Sethi Urology Institute, University of Miami, Miami, FL, University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
A PHASE IIB STUDY OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL ANTIBODY) WITH OR WITHOUT METHOTREXATE IN ADULTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE Org: Brigham and Women's Hospital, Boston, MA, Swedish Medical Center and University of Washington, Seattle, United States, Organizaciόn Medica de Investigaciόn, Buenos Aires, Argentina, Keio University, Tokyo, Japan, Csolnoky Ferenc Hospital, Veszprém, Hungary,
Abstract
ASSOCIATION OF RADIOGRAPHIC OUTCOMES WITH LOW DISEASE ACTIVITY AND REMISSION AND SUSTAINABILITY OF RESPONSE WITH SUBCUTANEOUS ABATACEPT OR ADALIMUMAB: 2-YEAR RESULTS FROM THE AMPLE TRIAL Org: University of Texas Southwestern Medical Center, Dallas, TX, University of Colorado Denver, Brigham & Women's Hospital, Boston, Bristol-Myers Squibb, Princeton, NJ, United States, Brigham and Women's Hospital, Boston, MA,